NASDAQConsumer StaplesHousehold & Personal ProductsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for UG yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain dividend payments | A primary condition in United-Guardian Inc's published investment case. The stated target is Dividend per share >= $0.25 in FY26. | Intact | Dividend per share falls below $0.25 in FY26 | Dividend per share: $0.25 per share FY2026-Q1; GAAP. Published target: Dividend per share >= $0.25 in FY26. Annual target cannot be compared with a quarterly or TTM observation. May 12, 20260.25 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Increase sales in 2026 | A primary condition in United-Guardian Inc's published investment case. The stated target is >=0% YoY revenue growth in FY26. | Intact | YoY revenue growth falls below 0% in FY26 | Revenue: $3.108M FY2026-Q2; GAAP. Published target: >=0% YoY revenue growth in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 20263,108,267 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Second quarter net sales increased by 10% from $2,838,225 in 2025 to $3,108,267 in 2026, with net income increasing 16% from $626,826 ($0.14 per share) to $728,579 ($0.16 per share).” ““With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our “natural” product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026.”” Revenue was $3.108 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Maintain valuation discount to peers | Its valuation is cheaper than peers with a P/E of 14.3 versus 17.5. | Intact | P/E rises above 17.5 sustainably | P/E (TTM): 12.67x As of 2026-11-04; trailing twelve months. The target timing and basis require a separate assessment. Nov 4, 202612.6709 ratio · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
UG is a consumer-staples business with a mildly favorable, intact long-term thesis rather than a turnaround story. Recent performance is strong and management appears stable, but earnings quality is neutral and overall risk is elevated.
The valuation evidence points to UG being cheap versus peers, with a negative expectations gap suggesting that expectations are not demanding. The evidence labels the pricing as justified and fragility as low, though it also notes weak execution quality; these signals support a restrained view rather than a strong valuation claim.
Near term, management is delivering on its stated sales-growth priority, with revenue growth across the reported year-over-year comparisons, and it recently increased the dividend. The multi-year thesis still depends on that execution continuing, while the next guidance update and weakening job growth are key near-term risks.
A guidance cut would be a meaningful negative, and further weakening in job growth could add pressure because UG is exposed to cyclical concerns. Continued earnings strength and higher guidance from sector peers such as PG, UL, and CL would support the sector backdrop and the case for UG’s recent momentum.
Over the next 1 to 3 years, UG’s thesis looks intact but carries elevated risk: sales growth and dividend delivery are encouraging, while execution quality and the next guidance update remain important checks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.